One of the greatest risks for oncology trials today is the delay in clinical development timelines. The main reason for the timeline delay is patient recruitment. Due to the increase in the number of ongoing clinical trials in recent years, and subsequently decreased enrollment in the developed countries, innovative approaches are necessary to mitigate the risk of delay.

To meet clinical development timelines, proactive planning and comprehensive data analysis are necessary to mitigate the risk. Detailed planning and appropriate site and country selection are the most critical factors in meeting target patient accrual goals. This audio conference provides practical guidelines and innovative ideas which are useful when conducting oncology trials in the current environment.

This audio conference covers:

• Analysis of the competitive landscape by region/country
• Evaluation of disease burden and standard of care by region/country
• Survey-based feasibility
• Anticipation of trial publications and drugs approvals, and the potential impact on standard of care

About the speaker:

Dr. Ute Berger is board-certified in Internal Medicine, Hematology and Medical Oncology, with special expertise in leukemias and lymphomas. Dr. Berger received her MD from the University of Heidelberg, and has served in senior positions on the Faculty of Clinical Medicine Mannheim, University of Heidelberg. She has extensive experience in clinical trials and over 18 years of clinical experience in academia. She is also certified by the European Society of Medical Oncology (ESMO).

Dr. Berger has held numerous prestigious professional positions, including serving as the Medical Coordinator for the German CML Study Center, General Manager of the German Competence Network “Acute and Chronic Leukemias” and as Scientific Network Manager of the “European LeukemiaNet," as well as a board member of the Telematikplattform eV, a platform for medical research networks. She has specific expertise and a strong interest in clinical research in hematology and oncology, and has published extensively in prominent journals.

Who should attend?

• Heads of Research & Development
• VPs of Clinical Development
• Directors of Clinical Operations
• Therapeutic Area Leaders
• Program & Clinical Study Managers
• Directors of Outsourcing and Procurement
• VPs of Global Data Management